Drug Profile

Research programme: humabody based cancer therapeutics - Crescendo Biologics/Takeda

Alternative Names: Humabody^® drug conjugates - Crescendo Biologics/Takeda; Humabody^® therapeutics - Crescendo Biologics/Takeda

Latest Information Update: 10 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Oct 2023 Preclinical development is ongoing in Cancer in United Kingdom (unspecified) (Crescendo Biologics pipeline, October 2023)
29 Dec 2020 The anti-cancer therapeutics programme is still in preclinical development (Crescendo Biologics pipeline, December 2020)
11 Dec 2020 Crescendo Biologics expands its global, multi-target discovery and development collaboration with Takeda

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com